News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
February, 2025
February 2025
M T W T F S S
 12
3456789
10111213141516
17181920212223
2425262728  
Pertuzumab Retreatment for Human Epidermal Growth Factor Receptor 2–Positive Locally Advanced/Metastatic Breast Cancer
Breast Cancer
Jan 29, 2025, 08:05

Pertuzumab Retreatment for Human Epidermal Growth Factor Receptor 2–Positive Locally Advanced/Metastatic Breast Cancer

Paolo Tarantino, Advanced research fellow at Dana-Farber Cancer Institute, shared a post on X:

“Final analysis of the PRECIOUS phase 3 trial out in Journal of Clinical Oncology. Despite yielding only a small PFS advantage, pertuzumab rechallenge in HER2+ MBC led to a relevant OS benefit (Δ 10 mo). Could become actionable if T-DXd/pertuzumab make it to the first line.”

Pertuzumab Retreatment for Human Epidermal Growth Factor Receptor 2–Positive Locally Advanced/Metastatic Breast Cancer

Pertuzumab Retreatment for Human Epidermal Growth Factor Receptor 2–Positive Locally Advanced/Metastatic Breast Cancer (PRECIOUS Study): Final Overall Survival Analysis

Authors: Yutaka Yamamoto,  Hiroji Iwata, Shigehira Saji, Masato Takahashi, Tetsuhiro Yoshinami, Takayuki Ueno, Tatsuya Toyama,  Takashi Yamanaka, Toshimi Takano, Masahiro Kashiwaba, Koichiro Tsugawa, Yoshie Hasegawa, Kenji Tamura,  Fumikata Hara, Tomomi Fujisawa, Naoki Niikura, Naruto Taira, Satoshi Morita,  Masakazu Toi, Shinji Ohno Norikazu Masuda

Pertuzumab Retreatment for Human Epidermal Growth Factor Receptor 2–Positive Locally Advanced/Metastatic Breast Cancer

cancer Fumikata Hara Hiroji Iwata Kenji Tamura Koichiro Tsugawa Masahiro Kashiwaba Masakazu Toi Masato Takahashi Naoki Niikura Naruto Taira OncoDaily Oncology Paolo Tarantino Satoshi Morita Shigehira Saji Shinji Ohno Norikazu Masuda Takashi Yamanaka Takayuki Ueno Tatsuya Toyama Tetsuhiro Yoshinami Tomomi Fujisawa Toshimi Takano Yoshie Hasegawa Yutaka Yamamoto
Special Coverage
Oncolibrary
Feb 26, 2025, 18:07
Ocular Side Effects of Chemotherapy: Understanding the Risks of Eye Toxicity
Blog
Feb 26, 2025, 16:35
Toral Shah: World cancer day 2025 reflections – Why is Integrative oncology important?
Science
Feb 26, 2025, 16:33
Hagop Kantarjian: Treatment-free remission in non-transplanted Ph+ ALL patients
Blog
Feb 26, 2025, 16:33
Iván R. González: Neoadjuvant Nivolumab Plus Ipilimumab versus Chemotherapy in Patients with Resectable NSCLC
Blog
Feb 26, 2025, 16:32
What can the EU do to strengthen women's cancer rights? - European Cancer Organisation
Science
Feb 26, 2025, 16:32
Clonal Hematopoiesis in Women With Breast Cancer
Blog
Feb 26, 2025, 16:31
No human should ever ignore a "Blood in their Stool" - Project PINK BLUE
Blog
Feb 26, 2025, 16:30
Reduced-volume vs conventional-volume radiotherapy after induction chemotherapy in nasopharyngeal carcinoma
Blog
Feb 26, 2025, 15:51
Tracey O'Brien: The Cancer Institute NSW annual Reporting Better Cancer Outcomes review meeting
Blog
Feb 26, 2025, 15:47
European School of Oncology's Update in Clinical Oncology course is available
Career
Feb 26, 2025, 15:38
UICC is looking for a Social Media and Content Specialist
Blog
Feb 26, 2025, 15:34
Sarah Louden: University of Kansas Breast Cancer Year in Review